Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Business Wire•27/10/2026•07:00 ET
0
Key Highlights
- ➤Faeth appoints Adam Schayowitz to its Board of Directors
- ➤Schayowitz brings nearly 20 years of oncology drug development experience
- ➤Schayowitz led multiple registration programs through regulatory approval
- ➤PIKTOR is being evaluated in Phase 1b/2 breast cancer trial
- ➤PIKTOR combines serabelisib and sapanisertib for endometrial and breast cancer
Expert Statements
Anand Parikh, Co-Founder and Chief Executive Officer of Faeth
“Adam brings experience in advancing oncology programs from early development through approval and commercialization, including in breast cancer, where we are evaluating PIKTOR in a Phase 1b/2 trial”
Adam Schayowitz, Executive Vice President and Head of Research and Development at Zymeworks; Faeth Board member
“I am pleased to join the Faeth Board of Directors as the Company advances PIKTOR, an all-oral multi-node inhibitor of the PI3K/AKT/mTOR pathway”
Adam Schayowitz, Executive Vice President and Head of Research and Development at Zymeworks; Faeth Board member
“I look forward to working with the Board and management team to support its clinical development”
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Dr. Schayowitz brings nearly 20 years of oncology drug development experience, including development leadership roles at Pfizer Oncology and Tesaro
Get started
Create a free account to read the full story.